Big Pharma Is Racing to China as Faster Trial Timelines Reshape Drug Development

Some of the world's largest drugmakers are leaning further into China's drug development ecosystem, drawn by a speed advantage that has become too large to ignore. China has cut the time it takes to go from early drug discovery to filing an application to begin human trials by 50% to 70%, according to a McKinsey analysis, a shift that is reshaping where global pharmaceutical companies choose to run their earliest-stage research.

A regulatory overhaul behind the speed

The driver behind that acceleration is not lower costs alone but a genuine overhaul of China's drug regulatory system. The country's drug regulator has rebuilt its review processes over the past several years, trimming bureaucratic steps that, in many other major markets, still stretch the path from lab discovery to first clinical trial into a multi-year slog. For global drugmakers under constant pressure to get promising compounds into human testing faster, that kind of structural speed advantage is difficult to match by simply spending more money elsewhere.

Roche moves from licensing to discovery

Roche has been among the most active players, signing ten licensing agreements with China-based drugmakers since the start of 2025, including its latest deal with Rona Therapeutics. More significantly, Roche has also begun partnering directly with Chinese biotech startups on early-stage drug discovery itself, including a tie-up with Defand Therapeutics, rather than simply licensing compounds that Chinese companies have already developed. That shift, from buying finished research to co-creating it, signals a deeper level of commitment to China's R&D ecosystem than a standard licensing deal implies.

AstraZeneca and Novartis place their own bets

AstraZeneca has gone further still, committing to invest $15 billion in China through 2030 to expand both medicines manufacturing and R&D capacity in the country. Novartis, meanwhile, has struck a deal with a Chinese biotech worth up to $7.8 billion, one of the largest in a recent wave of similar tie-ups between global pharmaceutical giants and Chinese drug developers. Taken together, the scale of commitment from Roche, AstraZeneca, and Novartis makes clear this is an industry-wide pivot rather than one company's experiment.

Speed comes with open questions

The rush toward China's drug development pipeline is not without friction. As more early-stage research moves into the country, questions persist around trial safety standards and transparency, concerns that matter more, not less, as the volume and pace of work flowing through China's system keeps climbing. How regulators, both in China and in the home markets of companies like Roche, AstraZeneca, and Novartis, manage that tension will likely shape how durable this shift proves to be.

What it means beyond China

For the rest of the world, including patients across Asia who may eventually benefit from drugs developed on these faster timelines, the practical effect is straightforward: if China's regulatory speed advantage holds, more of the earliest, highest-risk stages of drug development will increasingly happen there first. That reshapes not just where pharmaceutical investment flows, but potentially how quickly new treatments reach patients everywhere else, once those drugs eventually clear the additional regulatory hurdles required outside China.